Why Choose Us for Lymphoma Care?

Nurses in a hallway

There are many advantages to choosing a top cancer program like the one at the University of Chicago Comprehensive Cancer Center. Our patients benefit from the expertise of internationally known specialists who offer the most advanced treatments available for all types of lymphoma.

Access to Novel Drug Therapies

Chemotherapy is the first line of treatment for most lymphomas. Because many of our physicians are nationally renowned for their clinical and research expertise, our cancer programs are often among the first in the country to test new lymphoma drugs via clinical trials sponsored by the National Cancer Institute and by pharmaceutical companies. We currently offer fifteen different clinical trials for different subtypes of lymphoma at various stages, including Phase 1 and Phase 2 trials.
Some of the revolutionary new drug therapies being tested include:

  • Targeted therapies, such as monoclonal antibodies or radio-immunotherapy, that attack specific cancer pathways, leaving healthy cells unharmed
  • New chemotherapy agents that offer hope for lymphomas that have not responded to standard treatments and may have fewer side effects

Stem Cell Transplant

On April 10, 2010, dozens of stem cell transplant recipients and their families gathered at the University of Chicago Medicine campus to share their stories of survival. Hear the stories from patients who have recovered from leukemia and other blood cancers thanks to stem cell transplants, the donors who provided stem cells to loved ones, and the medical staff that cared for them before, during and after the procedure.

We take an aggressive approach to treating lymphomas that return after initial treatment and we consider stem cell transplant when appropriate for the patient. About 40 percent of patients of some types of lymphoma can be cured with autologous stem cell transplant - the use of a patient’s own stem cells. The University of Chicago is also a leader in allogeneic stem cell transplant -- the use of donated stem cells. Physicians and researchers in the program are continually looking for ways to improve the efficacy of stem cell transplantation and to minimize the side effects associated with this treatment.

Top Diagnostic Expertise

Some types of lymphoma are notoriously difficult to diagnose. Because of their extensive knowledge and experience, our world-renowned hematopathologoists can accurately identify even the most rare and complex cases, aiding our clinicians in planning the most effective treatments. Physicians from around the world consult with our hematopathologoists on complicated lymphoma cases.

The University of Chicago Medicine campus has the most advanced equipment available for diagnosing and staging lymphoma, including a combination PET-CT scanner.

Individualized Care Backed by a Multidisciplinary Team

While your care will be directed by physicians and nurses who specialize in the diagnosis and treatment of lymphoma, it will also benefit from the knowledge and expertise of many clinicians, researchers and other specialists at the University of Chicago Medicine campus.

University of Chicago cancer specialists meet weekly to discuss each patient’s case and to design individualized treatment plans. The multidisciplinary lymphoma team includes specialists in the areas of:

  • Hematology/oncology
  • Hematopathology
  • Radiation oncology
  • Neuro-oncology
  • Infectious disease
  • Social work
  • Nursing

Basic, Translational and Clinical Research

More than ever before, physicians and researchers are focusing on how basic research can be quickly and effectively translated to patient care. Behind the scenes our lymphoma specialists are focusing their research on understanding immune resistance in patients with advanced malignancies, identifying new targets for anti-cancer therapy, developing promising new agents for lymphomas and exploring novel strategies for autologous and allogeneic stem cell transplantation.

Our physicians are leaders in several major national organizations dedicated to cancer research including:

  • The Cancer and Leukemia Group B (CALGB). CALGB, a national research group headquartered at The University of Chicago, is dedicated to “bringing clinical oncologists and laboratory investigators together to develop better treatments for cancer.”
  • The Center for International Blood and Marrow Transplant Research (CIBMTR) is an "organization of basic and clinical scientists researching issues in blood and marrow transplantation."

A Legacy in Lymphoma Care

The University of Chicago Medical Center has a proud history in lymphoma care. More than 40 years ago, University of Chicago physician John E. Ultmann, MD, and his colleagues were instrumental in defining an approach to diagnosis, staging and treatment of lymphomas that still guides lymphoma care today.

Our lymphoma specialists carry on Dr. Ultmann’s legacy -- in their ongoing research and in their dedication to understanding and sharing their knowledge of the disease. Each year specialists from around the country gather at the International Chicago Lymphoma Symposium, co-sponsored by the University of Chicago Comprehensive Cancer Center, to discuss the treatment of malignant lymphomas in adult patients.

More Information